JP2023513073A5 - - Google Patents

Info

Publication number
JP2023513073A5
JP2023513073A5 JP2022546537A JP2022546537A JP2023513073A5 JP 2023513073 A5 JP2023513073 A5 JP 2023513073A5 JP 2022546537 A JP2022546537 A JP 2022546537A JP 2022546537 A JP2022546537 A JP 2022546537A JP 2023513073 A5 JP2023513073 A5 JP 2023513073A5
Authority
JP
Japan
Prior art keywords
composition according
hrsv
glycoprotein
lipids
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015840 external-priority patent/WO2021155243A1/en
Publication of JP2023513073A publication Critical patent/JP2023513073A/ja
Publication of JP2023513073A5 publication Critical patent/JP2023513073A5/ja
Pending legal-status Critical Current

Links

JP2022546537A 2020-01-30 2021-01-29 呼吸器系ウイルス免疫化組成物 Pending JP2023513073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062967888P 2020-01-30 2020-01-30
US62/967,888 2020-01-30
PCT/US2021/015840 WO2021155243A1 (en) 2020-01-30 2021-01-29 Respiratory virus immunizing compositions

Publications (2)

Publication Number Publication Date
JP2023513073A JP2023513073A (ja) 2023-03-30
JP2023513073A5 true JP2023513073A5 (enExample) 2024-07-01

Family

ID=77079256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546537A Pending JP2023513073A (ja) 2020-01-30 2021-01-29 呼吸器系ウイルス免疫化組成物

Country Status (11)

Country Link
US (1) US20230338506A1 (enExample)
EP (1) EP4096683A4 (enExample)
JP (1) JP2023513073A (enExample)
KR (1) KR20220133911A (enExample)
CN (1) CN115103682A (enExample)
AU (1) AU2021214774A1 (enExample)
BR (1) BR112022015053A2 (enExample)
CA (1) CA3169664A1 (enExample)
IL (1) IL295148A (enExample)
MX (1) MX2022009429A (enExample)
WO (1) WO2021155243A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
CN108430456B (zh) 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
JP6983455B2 (ja) 2016-09-14 2021-12-17 モデルナティーエックス, インコーポレイテッド 高純度rna組成物及びその調製のための方法
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
JP2022521094A (ja) 2019-02-20 2022-04-05 モデルナティエックス インコーポレイテッド 共転写キャッピング用rnaポリメラーゼバリアント
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN113521269A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022221336A1 (en) * 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN120153078A (zh) * 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
WO2024193965A1 (en) * 2023-03-17 2024-09-26 Glaxosmithkline Biologicals Sa Rsv-f-encoding nucleic acids
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
TW202508620A (zh) * 2023-05-10 2025-03-01 尼可拉斯 克拉克 呼吸道mrna組合疫苗
WO2024260446A1 (zh) * 2023-06-21 2024-12-26 深圳深信生物科技有限公司 呼吸道合胞病毒(rsv)疫苗
CN119979573A (zh) * 2023-11-03 2025-05-13 纳美信(上海)生物科技有限公司 一种呼吸道合胞病毒mRNA疫苗
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽
CN118064456B (zh) * 2024-03-01 2024-10-29 嘉译生物医药(杭州)有限公司 一种针对人合胞病毒的新型的RSV B mRNA疫苗
WO2025250938A2 (en) 2024-05-31 2025-12-04 Modernatx, Inc. Respiratory syncytial virus and metapneumovirus vaccines
WO2025260633A1 (zh) * 2024-06-19 2025-12-26 厦门万泰沧海生物技术有限公司 Rsv和hmpv融合f蛋白及其用途
CN118480560B (zh) * 2024-07-09 2024-11-26 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
CN120118162B (zh) * 2025-03-07 2026-03-10 深圳华大火眼工程科技有限公司 一种呼吸道合胞病毒的f蛋白突变体、其组合及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000036A (es) * 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
PT2970398T (pt) * 2013-03-13 2024-06-07 The Us Secretary Department Ofhealth And Human Servic Proteínas f de pré-fusão do vsr e sua utilização
MD3718565T2 (ro) * 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
TN2018000154A1 (en) * 2015-10-22 2019-10-04 Modernatx Inc Respiratory syncytial virus vaccine
CN115960263A (zh) * 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN110167587A (zh) * 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
EP3551193A4 (en) * 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
MA47787A (fr) * 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
SG11201908999QA (en) * 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
WO2019148101A1 (en) * 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
DE202019006199U1 (de) * 2018-04-17 2026-01-12 CureVac SE Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung

Similar Documents

Publication Publication Date Title
JP2024503699A5 (enExample)
DE112021000012C5 (de) Coronavirus-Vakzine
US11471525B2 (en) Coronavirus vaccine
JP2024503698A5 (enExample)
US20230302112A1 (en) Respiratory synctial virus rna vaccine
CA2760776C (en) Lipid compositions for the delivery of therapeutic agents
CA2751342C (en) Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
JP2023531511A5 (enExample)
JP2022535006A (ja) 増殖t細胞アッセイ
JP2024514182A5 (enExample)
CN116617382B (zh) 新型冠状病毒疫苗及其制备方法和应用
JP2022516356A (ja) 原発性線毛機能不全症の治療のための組成物および方法
US12263213B2 (en) Compositions for use in treatment of Chlamydia
KR20250099727A (ko) 호흡기 세포융합 바이러스 rna 백신접종
WO2024260446A1 (zh) 呼吸道合胞病毒(rsv)疫苗
JP2002512003A (ja) パラミキソウイルスワクチンのためのアルファウイルスベクター
JPWO2021251453A5 (enExample)
AU2021244684A1 (en) Compositions and methods for treating and preventing coronaviruses
JP2025510777A5 (enExample)
JPWO2022244815A5 (enExample)
CN118562832A (zh) 编码HTNV包膜糖蛋白GP的基因、其编码的表达载体、mRNA分子及其用途
JP2025529906A (ja) コロナウイルスに対するワクチン
JP2025512049A5 (enExample)
WO2025162490A1 (zh) 一种新型mRNA疫苗的制备及其在治疗乙型肝炎病毒疾病药物组合中的应用
CA3296649A1 (en) Respiratory syncytial virus (rsv) vaccine